INTRODUCTION AND OBJECTIVES:
Upper urinary tract urothelial carcinoma (UTUC) is a relatively rare disease which accounts for 5-10% of all urothelial malignancies, and its molecular biology is poorly understood. We comprehensively investigated the genetic alterations of this disease.
METHODS: Surgical specimens of UTUC and matched normal samples were obtained from 102 patients with various stages who underwent nephroureterectomy, and were subjected to whole exome/ RNA sequencing and methylation array.
RESULTS: UTUC displayed a large number of mutations with 5.3 mutations per megabase (Mb). 7 cases showed hypermutation (>20/Mb), 6 of which harbored biallelic mismatch repair (MMR) gene alterations, supporting UTUC is a Lynch syndrome-associated cancer. Genetic alterations were most frequently observed in TERT promoter (51% of cases), followed by KMT2D (48%), FGFR3 (46%, including fusion genes), CDKN2A (homozygous deletion) (42%), TP53 (31%), and RAS family genes (HRAS/KRAS/NRAS, 21%). More than 95% cases harbored either TP53, MDM2, FGFR3, or RAS alterations in almost mutually exclusive manner. Hierarchical clustering of frequently altered genes in 95 non-hypermutated cases identified 3 distinct subgroups. Group 1 is characterized by frequent TP53/MDM2 alterations with complex copy number alterations (CNAs), high stage/grade, and poor prognosis. Group2 is enriched in FGFR3 and CDKN2A alterations, showing simple CNAs, low stage/grade, and favorable prognosis. All cases in Group3 harbored RAS-family gene alterations. Gene expression analysis with unsupervised clustering identified 3 clusters. Cluster 1 was enriched for TP53 defective cases, showing high expression of late cell-cycle genes and basal markers. On the other hand, cluster 2 and 3 showed high expression of early cell cycle genes and luminal markers. Cases in cluster 2 were mainly FGFR3-mutanted cases (75%) while almost all of the RAS-mutated cases were classified in cluster 3 (92%). Notably, cluster 1, which showed poor prognosis, had significantly high expression of the immune blockade target CD274 and PDCD1LG2.Hierarchical analysis of methylation data revealed that approximately 60% of examined samples showed extensive hypermethylation (CIMPþ). However, there was no significant correlation with the mutation subtypes.
CONCLUSIONS: UTUC showed distinct genetic landscape in terms of mutations, which was also associated with prognosis, clinical features, and expression pattern. Our findings of molecular characteristics of UTUC will contribute to the development of new potential diagnostics and therapeutics. METHODS: Expression of IFIT5 in BCa tissues were investigated by immunohistochemical staining and database (TCGA and GEO) retrieving. Stable IFIT5 over-expression or knock-down BCa cell sublines were generated to investigate the role of IFIT5 on epithelialmesenchymal transition (EMT), cell migration and invasion in vitro. MicroRNA PCR array and qRT-PCR were used to verify the specific microRNA regulated by IFIT5. Direct target of the specific microRNA was verified by dual luciferase reporter assay, and their relationship with IFIT5 was analyzed by western blot. Subcutaneous xenograft model was used to investigate the effects of IFIT5 on tumorigenesis and verify the in vitro data.
RESULTS: IFIT5 expression was higher in high-grade, carcinoma in situ (CIS)-positive or muscle-invasive BCa tissues, which predicted a poor survival of patients. Over-expression of IFIT5 in 5637 and 253J cells induced EMT, promoted cell migration and invasion, and decreased the expression of mature miR-99a, meanwhile knock-down of IFIT5 in UM-UC-3 and TCCSUP cells inhibited EMT, suppressed cell migration and invasion, and increased the expression of mature miR99a. However, either over-expression or knock-down of IFIT5 had no effect on the expression of pre-miR-99a and pri-miR-99a. Furthermore, ICAM1 was shown as a direct target of miR-99a, and over-expression of miR-99a in IFIT5 over-expressing 5637 and 253J cells could reverse EMT, suppress cell migration and invasion, and decrease ICAM1 expression induced by IFIT5. In addition, overexpression of IFIT5 could enhance BCa tumorigenecity, and the expression of mature miR-99a was negatively regulated.
CONCLUSIONS: Interferon-induced gene IFIT5 may acts as an oncogene in BCa relapse and progression after BCG treatment, which induces EMT, promote cell migration and invasion, and increase the expression of ICAM1 via down-regulation of mature miR-99a.
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